Greenwich LifeSciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 7
- Market Cap
- $183.8M
- Introduction
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects
Phase 3
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Biological: PlaceboBiological: GLSI-100
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Greenwich LifeSciences, Inc.
- Target Recruit Count
- 598
- Registration Number
- NCT05232916
- Locations
- 🇪🇸
Hospital Universitario Donostia, San Sebastián, Spain
🇪🇸Hospital Universitari General de Catalunya - Grupo Quirónsalud, Sant Cugat Del Vallès, Spain
🇪🇸Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz De Tenerife, Spain
© Copyright 2025. All Rights Reserved by MedPath